# Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial

> **NCT07639528** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Northwestern University** · enrollment: 44 (estimated)

## Conditions studied

- Resectable Intrahepatic Cholangiocarcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cisplatin
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Durvalumab
- **DRUG:** Futibatinib
- **DRUG:** Gemcitabine
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT07639528
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-12-10
- **Primary completion:** 2030-12-10
- **Final completion:** 2031-12-10
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639528, "Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07639528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*